Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1–34

Mice heterozygous for targeted disruption of Pthrp exhibit, by 3 months of age, diminished bone volume and skeletal microarchitectural changes indicative of advanced osteoporosis. Impaired bone formation arising from decreased BM precursor cell recruitment and increased apoptotic death of osteoblast...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Miao, Dengshun, He, Bin, Jiang, Yebin, Kobayashi, Tatsuya, Sorocéanu, Maria A., Zhao, Jenny, Su, Hanyi, Tong, Xinkang, Amizuka, Norio, Gupta, Ajay, Genant, Harry K., Kronenberg, Henry M., Goltzman, David, Karaplis, Andrew C.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Clinical Investigation 2005
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC1193882/
https://ncbi.nlm.nih.gov/pubmed/16138191
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI24918
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge